目的 觀察脈血康膠囊聯(lián)合丹參川芎嗪注射液治療短暫性腦缺血發(fā)作的臨床療效。方法 選取2015年1月-2015年12月陜西省丹鳳縣醫(yī)院收治的短暫性腦缺血發(fā)作患者106例，隨機(jī)分為對(duì)照組和治療組，每組各53例。對(duì)照組在常規(guī)治療基礎(chǔ)上靜脈滴注丹參川芎嗪注射液，10 mL加入250 mL生理鹽水，1次/d；治療組在對(duì)照組的基礎(chǔ)上口服脈血康膠囊，4粒/次，1次/d。兩組患者均連續(xù)治療4周。觀察兩組臨床療效，比較兩組治療前后凝血酶原時(shí)間（PT）、活化部分凝血活酶時(shí)間（APTT）、凝血酶時(shí)間（TT）、纖維蛋白原（FIB）、超敏C反應(yīng)蛋白（hs-CRP）和D-二聚體指標(biāo)水平。觀察兩組患者的不良反應(yīng)和6個(gè)月內(nèi)的復(fù)發(fā)情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為69.81%、88.68%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組PT、APTT、TT水平均顯著升高，F(xiàn)IB、hs-CRP、D-二聚體水平顯著降低，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的改善程度優(yōu)于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組6個(gè)月復(fù)發(fā)率明顯低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 脈血康膠囊聯(lián)合丹參川芎嗪注射液治療短暫性腦缺血發(fā)作臨床療效確切，不良反應(yīng)少，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Maixuekang Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in treatment of transient ischemic attack. Methods Patients (106 cases) with transient ischemic attack in Danfeng County Hospital in Shaanxi Province from January 2015 to December 2015 were randomly divided into control and treatment groups, each group had 53 cases. The patients in the control group were iv administered with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection, 10 mL added into normal saline 250 mL, once daily. The patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 4 grains/time, once daily. The patients in two groups were treated for 4 weeks. After treatment, the efficacy was evaluated, and the levels of PT, APTT, TT, FIB, hs-CRP, and D-dimer in two groups before and after treatment were compared. The adverse reactions and recurrence within 6 months in two groups were observed. Results After treatment, the efficacies in the control and treatment groups were 69.81% and 88.68%, respectively, and there were differences between two groups (P<0.05). After treatment, PT, APTT, and TT levels in two groups were significantly increased, FIB, hs-CRP, and D-dimer levels were decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the improvement degree of these observational indexes in the treatment group was significantly better than those in the control group, with significant difference between two groups (P<0.05). The recurrence rate within 6 months in the treatment group was obviously lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Maixuekang Capsules combined with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection has a significant clinical efficacy in treatment of transient ischemic attack with less adverse reactions, which has a certain clinical application value.